Control group:Maltodextrin 180mg/d

2 trials

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Conditions

Metabolic-associated fatty Liver disease

Early Phase 1

A randomized crossover controlled trial of puerarin for the treatment of metabolic-associated fatty liver disease

Active, not recruitingChiCTR2400094017

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineMetabolic-associated fatty Liver disease

Start: 2024-12-18Updated: 2025-01-06

A randomized controlled trial of Puerarin in the treatment of metabolism-related fatty liver disease

Active, not recruitingChiCTR2500097261

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineMetabolic-associated fatty Liver disease

Start: 2025-02-21Updated: 2025-02-24

Related Papers

Randomised, controlled, crossover clinical trial protocol of puerarin for the treatment of metabolic-associated fatty liver disease in China

BMJ Open2025-09-01

A novel multi-parameter MRI-based model for identification of high-risk metabolic dysfunction-associated steatohepatitis.

2025-08-21